UK NHS England MS Treatment algorithm
If you don’t know where you are going, all roads lead there; and in this case to alemtuzumab!
But can alemtuzumab puts its money where it’s mouth is?
In ECTRIMS we saw the publication of one their original clinical trial (CARE-MS II) follow up results after an 8 year period (see poster below).
- 56% (77% of the original participants were included in this analysis) required no further doses of alemtuzumab, i.e. only the first 2 cycles an year apart
- 88% relapse-free
- 78% with disease stability, i.e. stable or improved EDSS scores
- 67% free of MRI activity
- Brain volume loss from baseline though to yr8 was -1.83% (i.e. normal rate as those without MS)
- Side effects were the same as previously described
I’ll leave you to come to your own conclusions on these findings, but alemtuzumab is here to stay.